A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative UsersA Drug-Drug Interaction Study Between Fenofibric Acid and EfavirenzImmunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and EthanolThe Effect of Itraconazole on BCT197 Exposure in Healthy Male ParticipantsClinical Evaluation of Healthy Subjects Receiving Intradermal Saline Using the Microneedle Adapter (Model UAR-2S)A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
P6153
Q61909458-C2BB9541-2C52-4854-8A0B-89A59DFF4DA6Q61955459-EA0BD087-5331-4AAE-ADEA-D5808863C751Q61970011-F8F2E80D-1E42-44A5-AD2C-78D44F7B1702Q63315541-E7CB68D0-8E9D-444F-8E08-7078D5B62B03Q63399874-5CAF5E79-C1B7-4275-8ACB-272148FA74B2Q63405082-BF56C46F-FF0A-4572-A16B-1B777D43D4ECQ63570982-A223BD75-B872-4D25-A761-3219CE0D6674
P6153
description
Contract research organization
@en
Dienstleistungsunternehmen für die (Bio-)Pharma- und Medizintechnikindustrie
@de
entreprise pharmaceutique
@fr
name
InVentiv Health Clinique
@fr
Syneos Health
@de
Syneos Health
@en
type
label
InVentiv Health Clinique
@fr
Syneos Health
@de
Syneos Health
@en
altLabel
INC Research
@en
inVentiv Health
@en
prefLabel
InVentiv Health Clinique
@fr
Syneos Health
@de
Syneos Health
@en
P2671
P159
P2002
SyneosHealth
P2003
syneoshealth
P2427
grid.497427.b
P2561
Syneos Health
@en
P2671
/g/11bc69f2_z
P571
1999-01-01T00:00:00Z
P6782
P946
US87166B1026